Physician profile
Linzi E Leighton
NPI 1962747238
$16,352.21
in general payments reported to CMS, 2019-2025
36 companies · $3,440 in 2025
The $3,440 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,350 · 2022: $2,984 · 2023: $2,748 · 2024: $2,830 · 2025: $3,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,965 · Education: $53.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,964.86 |
| Education | $53.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,034.37 | 2021-2025 | |
| Eisai INC. | $1,812.29 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,717.68 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,546.25 | 2021-2025 | Caplyta |
| Lundbeck LLC | $812.82 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $793.37 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $725.72 | 2021-2025 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $711.89 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Supernus Pharmaceuticals, INC. | $666.64 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $641.54 | 2021-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $588.40 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $556.18 | 2021-2022 | |
| Bausch Health US, LLC | $525.36 | 2021-2025 | Aplenzin |
| Alkermes, INC. | $457.46 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $378.41 | 2022-2025 | Auvelity, Sunosi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $373.46 | 2021-2025 | Ingrezza |
| Neos Therapeutics, LP | $364.94 | 2021-2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $340.06 | 2023-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $282.66 | 2021-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $214.72 | 2022-2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $117.35 | 2024-2025 | Cobenfy |
| Biogen, INC. | $112.33 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $110.94 | 2021-2022 | |
| Livanova USA, INC. | $86.27 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Idorsia Pharmaceuticals US INC | $66.05 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $63.88 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $43.09 | 2025 | Relexxii |
| Neuronetics, INC. | $34.78 | 2025 | Neurostar Tms Therapy System |
| Indivior INC. | $33.06 | 2022-2023 | Perseris |
| Merck Sharp & Dohme LLC | $32.88 | 2022 | |
| Sage Therapeutics, LLC | $26.58 | 2021 | |
| Tempus Ai, INC | $25.01 | 2025 | Tempus Pixel |
| Adlon Therapeutics L.P. | $21.00 | 2021 | |
| Currax Pharmaceuticals LLC | $13.70 | 2021 | |
| Owp Pharmaceuticals, INC. | $12.42 | 2021 | |
| Aytu Biopharma, INC. | $8.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linzi Leighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.